Drug Discovery World

DECEMBER 9, 2022

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial. . The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. . months to 7.2

Trials 52

Trials Hormones Drugs Genetics 52

Pharmaceutical Technology

MAY 31, 2023

The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). Les Laboratoires Servier overview Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. It is administered as an intravenous infusion.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

Drug Discovery World

DECEMBER 19, 2023

Astellas’ Veoza (fezolinetant) will soon be available to some women in the UK suffering from vasomotor symptoms (VMS) associated with menopause following approval by the Medicines and Healthcare Regulatory Agency (MHRA). Worldwide, more than half of women 40 to 64 years of age experience VMS, with rates in Europe ranging from 56% to 97%.

Hormones 59

Hormones Clinical Trials Clinical Trials Medicine 59

Drug Discovery World

AUGUST 16, 2023

The study, by researchers at The Institute of Cancer Research, London, shows that certain characteristics within patients’ primary tumours can predict how they will respond to different treatments after their tumours have spread around the body.

Genetics 52

Genetics Gene Hormones RNA 52

Drug Discovery World

AUGUST 31, 2022

A new therapeutic approach for triple negative breast cancer using nitric oxide is being explored by researchers at the medical research centre CÚRAM. Triple-negative breast cancer is invasive breast cancer that does not respond to hormonal therapy medicines or the current medicines that target the HER2 protein.

Hormones 52

Hormones Doctors Doctor Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Alkaloids, natural dyes, drugs, proteins, and enzymes are some of the important classes of natural heterocyclic compounds essential for human life. The company filed heterocyclic composition patents in areas such as PAD4 inhibitors, factor Xa inhibitors, and nuclear hormone receptor modulators.

Antibody 130

Antibody Hormones DNA Licensing 130

The Pharma Data

SEPTEMBER 28, 2021

Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Merck has the industry’s largest immuno-oncology clinical research program. About Triple-Negative carcinoma.

Hormones 52

Hormones Medicine Clinical Research Research 52

The Pharma Data

DECEMBER 9, 2020

The trial, conducted in nine countries, found that adding chemotherapy to hormone-blocking drugs brought no added benefit to a particular group of patients. Those were postmenopausal women with hormone-sensitive breast cancer that had spread to only one to three lymph nodes, and who had a low risk of recurrence.

Hormones 52

Hormones Trials Medicine Clinical Trials 52

Roots Analysis

OCTOBER 24, 2023

Owing to the advancement in clinical pharmacology and oncology domain, and the rising demand for targeted therapeutics and precision medicines, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become one of the key areas of interest to researchers and drug manufacturers across the globe.

Manufacturing 40

Manufacturing Hormones Contamination Contract Manufacturing 40

Roots Analysis

JANUARY 23, 2024

Owing to the challenges involved in the synthesis process and demands of modern drug development, majority of drug developers in this domain prefer to outsource their development and manufacturing operations to peptide therapeutics contract API manufacturers as a strategic solution to streamline their research and peptide synthesis efforts.

Development 40

Development Contract Manufacturing Drugs Manufacturing 40

The Pharma Data

JANUARY 7, 2021

Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some of the assets that will be key revenue drives for the company. That’s a significant goal. “In

Protein 52

Protein Antibody Genetics Gene Therapy 52

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. The disorder can occur at any stage of life and vary with severity.

Hormones 52

Hormones Marketing Gene Trials 52

Drug Discovery World

JUNE 1, 2023

A market research report published in late June 2018 by HTF market Intelligence Consulting suggested that the ADC market in China would grow exponentially by 2023 4. Under the terms of the licensing agreement, AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305.

Antibody 98

Antibody Marketing Drugs Licensing 98

Velocity Clinical Research

JUNE 27, 2023

The prolific researchers also had findings simultaneously published in the New England Journal of Medicine and The Lancet. “It’s a chemical, a small molecule that also acts on the GLP-1 receptor, but because it’s not a protein it’s not degraded by enzymes,” said Dr. Frias.

Insulin 52

Insulin Trials Hormones Clinical Trials 52

The Pharma Data

MARCH 22, 2021

More than 15 dedicated early to late development and research programs underway to identify the next wave of radioligand therapies for cancer. These groundbreaking data confirm our belief in the potential of 177 Lu-PSMA-617 to reimagine outcomes for these patients through phenotypic precision medicine.

Hormones 52

Hormones Gene Therapy Trials Medicine 52

Pfizer

JANUARY 27, 2023

Pfizer Responds to Research Claims carterda Fri, 01/27/2023 - 19:48 Pfizer Responds to Research Claims Friday, January 27, 2023 - 08:00pm Share New York, N.Y., In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.

Research 112

Research Vaccination Vaccine Drugs 112

The Pharma Data

APRIL 27, 2022

The Food and Drug Administration’s (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. 1-4 Low HER2 expression occurs in both HR-positive and HR-negative disease.

HR 52

HR Trials Protein Medicine 52

The Pharma Data

AUGUST 6, 2020

Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified. This includes studies evaluating Tecentriq both alone and in combination with other medicines. By inhibiting PD-L1, Tecentriq may enable the activation of T-cells.

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

AUGUST 30, 2021

TNBC remains the most challenging type of breast cancer to treat, which makes the decision to withdraw so difficult for us, as patients have had this medicine as an important option for more than two years,” said Levi Garraway, M.D., This is not related to any changes in either the efficacy or safety associated with Tecentriq. receptors.

Medicine 52

Medicine Antibody Hormones FDA Approval 52

Pfizer

AUGUST 15, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. Contraception : Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. 07.27.2022. 07.19.2022.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

SEPTEMBER 16, 2020

Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer. Gavreto is being jointly commercialised by Genentech, a wholly owned member of the Roche Group, and Blueprint Medicines in the U.S.

HR 52

HR Medicine Hormones Trials 52

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Recombinant therapeutic proteins. Fusion proteins. Gene and cellular therapies. Growth factors. Interferons.

Development 180

Development Protein Production Hormones 180

Drug Discovery World

AUGUST 31, 2023

Researchers have identified stem cells in the human thymus for the first time, representing a potential new target to understand immune diseases and cancer. They can develop into epithelial as well as muscle and neuroendocrine cells, highlighting the importance of the thymus in hormonal regulation.

Research 59

Research Immune Response Scientist Hormones 59

The Pharma Data

APRIL 27, 2021

The FDA’s Accelerated Approval Program allows for conditional approval of a medicine that fills an unmet medical need for a serious condition, with specific postmarketing requirements (PMRs) to confirm the clinical benefit and convert to regular approval. receptors.

Medicine 40

Medicine In-Vitro Antibody Development 40

Pfizer

JANUARY 27, 2023

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Marketing 75

Marketing Production Drugs Licensing 75

The Pharma Data

FEBRUARY 8, 2021

“The TITAN final analysis data confirm the long-term clinical benefit and consistent safety profile of ERLEADA ® plus ADT without a compromise in health-related quality of life,” said Mary Guckert, RN, MSN, Vice President, Development Leader, Prostate Cancer, Janssen Research & Development, LLC. About ERLEADA ® (apalutamide).

HR 52

HR Hormones Development Production 52

The Pharma Data

SEPTEMBER 19, 2020

This includes studies evaluating Tecentriq both alone and in combination with other medicines. About Roche in breast cancer Roche has been advancing breast cancer research for more than 30 years with the goal of helping as many people with the disease as possible. By inhibiting PD-L1, Tecentriq may enable the activation of T-cells.

HR 52

HR Medicine In-Vitro Development 52

The Pharma Data

FEBRUARY 1, 2021

1, 2021 (American Heart Association News) — Medical science has come a long way since the days of “bikini medicine,” when the only time doctors managed a woman’s health differently than a man’s was when treating the parts of her body found under a bikini. MONDAY, Feb. It’s that they age differently.

Hormones 40

Hormones Radiology Research Medicine 40

Drug Discovery World

APRIL 11, 2024

On the final day of AACR, the plenary session of the Annual Meeting put artificial intelligence at the forefront and featured a stellar lineup of AI and data science experts who discussed AI and topics such as imaging, precision medicine, and drug development. And thanks to the city of San Diego for its hospitality.”

HR 52

HR Antibody In-Vitro DNA 52

The Pharma Data

APRIL 23, 2021

The European Medicine Agency’s approval of dostarlimab is based on results from the multi-cohort GARNET study, which included women with recurrent or advanced dMMR/MSI-H endometrial cancer who progressed on or after a platinum-based chemotherapy regimen in cohort A1 (n=108 evaluable for efficacy). World Cancer Research Fund.

Antibody 52

Antibody Hormones Licensing Licensing 52

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. What does this Approval Mean for Breast Cancer Patients?

HR 52

HR Hormones FDA Approval Antibody 52

The Pharma Data

JANUARY 21, 2021

Researchers at Washington University School of Medicine in St. The research was published in the journal JCI Insight. The research team evaluated 97 patients with COVID-19 at Barnes-Jewish Hospital. The research was conducted in mice and humans. Every week there are numerous scientific studies published.

Research 52

Research DNA Hormones Vaccination 52

XTalks

AUGUST 10, 2022

HER2-low is characterized by the presence of some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive. The trial included 494 hormone receptor positive (HR+) patients and 63 hormone receptor negative (HR-) patients. The receptor is involved in promoting cell growth. Cancer Moonshot Program.

FDA Approval 98

FDA Approval HR Hormones Antibody 98

Scienmag

SEPTEMBER 15, 2020

Researchers develop a wider spectrum for dLight1 sensor, allowing multiplex imaging of neurotransmitters Credit: UC Regents Sacramento, CA– In 2018, Lin Tian and her team at UC Davis Health developed dLight1, a single fluorescent protein-based biosensor.

Hormones 55

Hormones Protein Development Research 55

Pfizer

DECEMBER 13, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Research Vaccines.

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

AUGUST 3, 2021

billion in acquired in-process research & development (acquired IPR&D) associated with our acquisition of Five Prime Therapeutics, partially offset by increased revenues. pts Research & Development $ 1,082 $ 964 12% $ 1,036 $ 936 11% % of product sales 17.7% GAAP earnings per share (EPS) decreased 73% to $0.81 39.3% (25.8)

Sales 52

Sales Production Antibody Development 52

XTalks

FEBRUARY 5, 2024

The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research. In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors.

FDA Approval 101

FDA Approval Drugs Sales Development 101